Statistik Asas
| CIK | 1739174 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BiomX Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 13, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-275935 PROSPECTUS SUPPLEMENT (to Prospectus dated January 2, 2024) Up to $1,765,939 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated January 2, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-275935), or the Registration Statement, as supplemented by our prospe |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name |
|
| August 13, 2025 |
Exhibit 99.1 BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of new BX004 Phase 1b/2a data demonstrated further ~500-fold (2.7 log₁₀)2 bacterial reductio |
|
| July 30, 2025 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 8, 2025 |
Exhibit 99.1 BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis Premier research journal article provides validation for BiomX’s phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections New, updated data demonstrates a further bacte |
|
| July 8, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 8, 2025 |
Exhibit 99.2 Corporate Presentation July 2025 Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance NYSE American: PHGE SAFE HARBOR STATEMENT About this Presentation The information contained in this presentation has been prepared by BiomX Inc. and its subsidiaries (collectively, the “Company” or “ BiomX ”) and contains information pertaining to the business and opera |
|
| June 9, 2025 |
Exhibit 99.1 Corporate Presentation June 2025 Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance NYSE American: PHGE SAFE HARBOR STATEMENT About this Presentation The information contained in this presentation has been prepared by BiomX Inc. and its subsidiaries (collectively, the “Company” or “ BiomX ”) and contains information pertaining to the business and opera |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Nam |
|
| May 15, 2025 |
Exhibit 99.1 BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warra |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 24, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-286496 PROSPECTUS BIOMX INC. Up to 2,305,869 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants Up to 5,939,383 Shares of Common Stock Issuable Upon Exercise of Common Warrants Up to 6,955,528 Shares of Common Stock Issuable Upon Exercise of New Warrants Offered by the Selling Securityholders Named Herein This prospectus relat |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 21, 2025 |
BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 April 21, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Tim Buchmiller Re: BiomX Inc. Registration Statement on Form S-1 Filed April 11, 2025 File No. 333-286496 (the “Registration Statement”) Request for Acceleration Ladies and Gentlemen: Pur |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 11, 2025 |
As filed with the Securities and Exchange Commission on April 11, 2025 As filed with the Securities and Exchange Commission on April 11, 2025 Registration No. |
|
| April 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwar |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 31, 2025 |
Exhibit 99.2 INVESTOR PRESENTATION March 2025 Revolutionizing the Treatment of Infections Associated with Chronic Disease Through Phage Therapy NYSE American: PHGE 1 SAFE HARBOR STATEMENT About this Presentation The information contained in this presentation has been prepared by BiomX Inc. and its subsidiaries (collectively, the “Company” or “ BiomX ”) and contains information pertaining to the bu |
|
| March 31, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 31, 2025 |
Exhibit 99.1 BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) ● BX211 was safe and well-tolerated ● BX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 25, 2025 |
Exhibit 99.1 BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates ● In February 2025, BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b study of BX004; topline results anticipated in Q1 2026 ● Topline Phase 2 results for BX211 in diabetic foot osteomyelitis (DFO) exp |
|
| March 25, 2025 |
Exhibit 10.34 MTEC Research Project Award Number: 001 MTEC Base Agreement Number: MTEC Project Call: MTEC; Development of Personalized Bacteriophage Therapeutic for the Treatment of Bacterial Infections PARTIES: Advanced Technology International (MTEC Consortium Manager) and Adaptive Phage Therapeutics, Inc (Awardee) This MTEC Research Project Award is issued under the authority of the MTEC Base A |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0001-38762 BIOMX INC. (Exact name of regi |
|
| March 25, 2025 |
BiomX Inc. Insider Trading Policy Exhibit 19.1 BIOMX INC. INSIDER TRADING AND BLACKOUT POLICY As of March 24, 2025 POLICY STATEMENT This document sets forth the policies of BiomX Inc. (the “Company”) prohibiting “insider trading” and the procedures to be followed by directors, officers, employees and other related persons of the Company before engaging in any trading involving securities of the Company. Insider trading is prohibit |
|
| March 25, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BiomX Inc., or the Company, we, us or our, has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act – shares of Common Stock, $0.0001 par value per share, or the Common Stock. The shares Common Stock r |
|
| March 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 27, 2025 |
Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 27, 2025 |
424B5 1 ea0232203-424b5biomx.htm PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) Registration No. 333-275935 PROSPECTUS SUPPLEMENT (To Prospectus January 2, 2024) 2,828,283 Shares of Common Stock Pre-Funded Warrants to Purchase up to 805,231 Shares of Common Stock Up to 805,231 Shares of Common Stock Underlying Such Pre-Funded Warrants Pursuant to this prospectus supplement and the accompan |
|
| February 27, 2025 |
Exhibit 10.3 BIOMX INC. February 25, 2025 Holder of Warrants Issued in March 2024 Re: Inducement Offer to Exercise Warrants Issued in March 2024 Dear Holder: BiomX Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and in c |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 27, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 25, 2025, by and among BiomX Inc., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. Subject to the terms and conditions set forth in |
|
| February 27, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 27, 2025 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 27, 2025 |
Exhibit 4.2 BIOMX INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant Shares: [] Date of Issuance: [] (“Issuance Date”) BiomX Inc., a company incorporated under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER], the registered holder hereof or its permitted assigns (the “Hold |
|
| February 27, 2025 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 27, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-278986 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2024) Up to 40 Warrants to Purchase up to 12,014,881 Shares of Common Stock 147,735 Shares of Series X Preferred Stock 38,620,078 Shares of Common Stock Consisting of: Up to 12,014,881 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 14,773,500 Shares of Common Stock Issu |
|
| February 27, 2025 |
Exhibit 99.1 BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million Proceeds to support advancement of BX004 program through Phase 2b study topline results in cystic fibrosis (CF) patients, anticipated in Q1 2026 Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes |
|
| February 27, 2025 |
Exhibit 10.4 PLACEMENT AGENCY AGREEMENT Laidlaw & Company (UK) Ltd. 521 5th Ave New York, NY 10175 February 25, 2025 Ladies and Gentlemen: This letter agreement (this “Agreement”) constitutes the agreement between BiomX Inc., a Delaware corporation (the “Company”) and Laidlaw & Company (UK) Ltd. (“Laidlaw”) pursuant to which Laidlaw shall serve as the placement agent (the “Placement Agent”) for th |
|
| February 27, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of February 25, 2025, by and among BiomX Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agree |
|
| February 27, 2025 |
Exhibit 99.2 INVESTOR PRESENTATION February 2025 Revolutionizing the Treatment of Infections Associated with Chronic Disease Through Phage Therapy NYSE American: PHGE 1 SAFE HARBOR STATEMENT About this Presentation The information contained in this presentation has been prepared by BiomX Inc. and its subsidiaries (collectively, the “Compa ny” or “BiomX”) and contains information pertaining to the |
|
| February 24, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-275935 Prospectus Supplement (To the Prospectus dated January 2, 2024) We previously entered into an At the Market Offering Agreement, or the offering agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated December 7, 2023, relating to the sale of shares of our common stock, par value $0.0001 per share, or our Common Stock, offered by |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact |
|
| November 14, 2024 |
Exhibit 10.1 BIOMX INC. 2019 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Unit Agreement This Restricted Stock Unit Agreement and the associated grant award information (the “Customizing Information”), which Customizing Information is provided in written form or is available in electronic form from the recordkeeper for the BiomX Inc. 2019 Omnibus Long-Term Incentive Plan (including any append |
|
| November 14, 2024 |
Exhibit 3.2 BIOMX INC. COMPOSITE CERTIFICATE OF INCORPORATION INCORPORATING: Amended and Restated Certificate of Incorporation filed December 13, 2018 Certificate of Amendment of Certificate of Incorporation filed October 28, 2019 Certificate of Amendment of Certificate of Incorporation filed August 31, 2022 Certificate of Amendment of Certificate of Incorporation filed July 9, 2024 Certificate of |
|
| November 14, 2024 |
Exhibit 99.1 BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now expected to report topline results in H1 2026 following resolved manufacturing delays Company to |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 14, 2024 |
Exhibit 3.1 BIOMX INC. COMPOSITE CERTIFICATE OF INCORPORATION INCORPORATING: Amended and Restated Certificate of Incorporation filed December 13, 2018 Certificate of Amendment of Certificate of Incorporation filed October 28, 2019 Certificate of Amendment of Certificate of Incorporation filed August 31, 2022 Certificate of Amendment of Certificate of Incorporation filed July 9, 2024 Certificate of |
|
| November 13, 2024 |
PHGE / BiomX Inc. / AMR Action Fund, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2428335d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09090D301 (C |
|
| November 4, 2024 |
PHGE / BiomX Inc. / Burbank John Howard III - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09090D301 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38762 BiomX Inc. (Exact name of registrant as specified in its charter) |
|
| October 28, 2024 |
SC 13G/A 1 ea0218399-sc13ga1centbiomx.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of |
|
| October 25, 2024 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 05, 2024, pursuant to the provisions of Rule 12d2-2 (a). |
|
| October 15, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number |
|
| September 26, 2024 |
Exhibit 99.1 R e v ol u tioni z i n g the T r e a tme n t of I n f e c t i o n s A s s oci a t e d wit h C hr onic D iseas e Th r oug h P ha g e Th e r a p y INVE S T O R P R ES E N T A T I ON SEP T EM BE R 2 0 24 N Y S E Ameri c a n : P HGE 1 SAFE H A RBOR STATEMENT A b ou t t h i s Pr e sent a t i on The information contained in this presentation has been prepared by BiomX Inc. and its subsidiar |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 12, 2024 |
Exhibit 107 Form S-8 (Form Type) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount registered(1)(2)(3) Proposed maximum offering price per share Proposed maximum aggregate offering price Fee Rate Amount of registration fee Equity Common stock to be issued under the Amended and Restated Charda |
|
| September 12, 2024 |
As filed with the Securities and Exchange Commission on September 12, 2024 As filed with the Securities and Exchange Commission on September 12, 2024 Registration No. |
|
| August 16, 2024 |
Form of Certificate of Amendment to Certificate of Incorporation of BiomX Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMX INC. (REVERSE STOCK SPLIT AMENDMENT) BiomX Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies: FIRST: That the Amended and Restated Certificate of Incorporation of the Corporatio |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2024 (August 16, 2024) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commi |
|
| August 14, 2024 |
Exhibit 3.2 BIOMX INC. COMPOSITE CERTIFICATE OF INCORPORATION INCORPORATING: Amended and Restated Certificate of Incorporation filed December 13, 2018 Certificate of Amendment of Certificate of Incorporation filed October 28, 2019 Certificate of Amendment of Certificate of Incorporation filed August 31, 2022 Certificate of Amendment of Certificate of Incorporation filed July 9, 2024 AMENDED AND RE |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name |
|
| August 14, 2024 |
Exhibit 3.1 BIOMX INC. COMPOSITE CERTIFICATE OF INCORPORATION INCORPORATING: Amended and Restated Certificate of Incorporation filed December 13, 2018 Certificate of Amendment of Certificate of Incorporation filed October 28, 2019 Certificate of Amendment of Certificate of Incorporation filed August 31, 2022 Certificate of Amendment of Certificate of Incorporation filed July 9, 2024 AMENDED AND RE |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 (July 23, 2024) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commissio |
|
| July 17, 2024 |
EX-99.1 2 ss3643748ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 5 to Schedule 13D, dated July 15, 2024, with respect to the common stock of BiomX Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersig |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* BiomX Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Carl L. Gordon Erez Chimovits 5 Hahoshlim Street Building B |
|
| July 16, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-278986 PROSPECTUS BIOMX INC. Up to 40 Warrants to Purchase up to 120,148,806 Shares of Common Stock 147,735 Shares of Series X Preferred Stock 386,200,774 Shares of Common Stock Consisting of: Up to 120,148,806 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 147,735,000 Shares of Common Stock Issuable Upon Conversion of the Seri |
|
| July 11, 2024 |
PHGE / BiomX Inc. / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.l 3d-l (a) AND AMENDMENTS THERETO FILED PURSUANT TO§ 240.13D-2(a) (Amendment No. 2)* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) David Clark Deerfield Management Compan |
|
| July 11, 2024 |
As filed with the Securities and Exchange Commission on July 11, 2024 As filed with the Securities and Exchange Commission on July 11, 2024 Registration No. |
|
| July 11, 2024 |
BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 CORRESP 1 filename1.htm BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 July 11, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Re: BiomX Inc. Registration Statement on Form S-3 Originally filed on April 29, 2024, as amended on July 9, 2024 and July 11, 2024 File No. 333-278986 |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 9, 2024 |
As filed with the Securities and Exchange Commission on July 9, 2024 As filed with the Securities and Exchange Commission on July 9, 2024 Registration No. |
|
| July 9, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMX INC. BiomX Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies: FIRST: That the Amended and Restated Certificate of Incorporation of the Corporation, as amended, be further amende |
|
| July 9, 2024 |
Exhibit 10.1 AMENDED AND RESTATED CHARDAN HEALTHCARE ACQUISITION CORP. LONG-TERM INCENTIVE PLAN TABLE OF CONTENTS Page No. SECTION 1 GENERAL 1 1.1. Purpose 1 1.2. Participation 1 1.3. Foreign Participants 1 1.4. Operation and Administration 1 1.5. History 1 SECTION 2 DEFINITIONS 1 SECTION 3 SHARES AND PLAN LIMITS 4 3.1. Shares of Stock and Other Amounts Subject to Plan 4 3.2. Adjustments 5 3.3. Pl |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| June 13, 2024 |
HAYNES AND BOONE, LLP 30 Rockefeller Plaza, 26th Floor New York, NY 10112 HAYNES AND BOONE, LLP 30 Rockefeller Plaza, 26th Floor New York, NY 10112 June 13, 2024 VIA EDGAR U. |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| May 30, 2024 |
Exhibit 99.1 AUDITED FINANCIAL STATEMENTS OF ADAPTIVE PHAGE THERAPEUTICS, INC. ADAPTIVE PHAGE THERAPEUTICS, INC. FINANCIAL STATEMENTS Years Ended December 31, 2023 and 2022 With Report of Independent Auditors ADAPTIVE PHAGE THERAPEUTICS, INC. AUDITED FINANCIAL STATEMENTS Years Ended December 31, 2023 and 2022 Report of Independent Auditors F-2 Balance Sheets F-4 Statements of Operations and Compre |
|
| May 30, 2024 |
PHGE / BiomX Inc. / Flynn James E - AMENDMENT NO. 1 TO SC 13D Activist Investment SC 13D/A 1 e663672sc13da-biomx.htm AMENDMENT NO. 1 TO SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.l 3d-l (a) AND AMENDMENTS THERETO FILED PURSUANT TO§ 240.13D-2(a) (Amendment No. 1)* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 090 |
|
| May 30, 2024 |
Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION (USD in thousands, except share and per share data) On March 6, 2024, BiomX Inc. (“the Company’), entered into the Merger Agreement (the “Merger Agreement”) with BTX Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), BTX Merger Sub II, LLC, a Delaware limited liabili |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT NO. 1 TO CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Com |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| May 20, 2024 |
Exhibit 10.2 BIOMX INC. Indemnification Agreement This Indemnification Agreement (this “Agreement”) is made as of, by and between BiomX Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases in the cost of such insu |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Nam |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: N/A Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| April 29, 2024 |
As filed with the Securities and Exchange Commission on April 29, 2024 As filed with the Securities and Exchange Commission on April 29, 2024 Registration No. |
|
| April 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 BIOMX INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effecti |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 15, 2024 |
Amended and Restated Bylaws of the Company, as amended on April 11, 2024 (marked copy) Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF BIOMX INC. (as amended on April 11, 2024) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the |
|
| April 15, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOMX INC. (as amended on April 11, 2024) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. All meetings of the stockholders shall be held at such place within or outside the State of Delaware as may be fixed from time to time by the Board of Directors or the chief executive officer, or if not so designated, at the registered office of the |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0001-38762 BIOMX INC. (Exact name of regi |
|
| April 4, 2024 |
Exhibit 10.24 CUI BIOLOGICAL MATERIALS LICENSE AGREEMENT PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. This Agreement is entered into between the Walter Reed Army Institute of Research (WRAIR) (hereinafter “LICENSOR”) a subordinate Laborator |
|
| April 4, 2024 |
Form of Indemnification Agreement Exhibit 10.3 BIOMX INC. Indemnification Agreement This Indemnification Agreement (this “Agreement”) is made as of, by and between BiomX Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases in the cost of such insu |
|
| April 4, 2024 |
Exhibit 21.1 BiomX Inc. Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation BiomX Ltd. Israel Adaptive Phage Therapeutics, LLC. Delaware, USA |
|
| April 4, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 BiomX Inc., or the Company, we, us or our, has three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: (i) shares of Common Stock, $0.0001 par value per share, or common stock; (ii) Units, each consi |
|
| April 4, 2024 |
Exhibit 10.30 SECOND AMENDMENT TO LEASE AGREEMENT PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THIS SECOND AMENDMENT TO LEASE AGREEMENT (“this Second Amendment”) is dated as of July 8, 2021 (“Second Amendment Effective Date”), by and betwee |
|
| April 4, 2024 |
Exhibit 10.33 FIFTH AMENDMENT TO LEASE AGREEMENT PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THIS FIFTH AMENDMENT TO LEASE AGREEMENT (“this Fifth Amendment”) is dated as of February 2, 2023 (“Fifth Amendment Effective Date”), by and betwee |
|
| April 4, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 4, 2024 |
Exhibit 10.31 THIRD AMENDMENT TO LEASE AGREEMENT PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THIS THIRD AMENDMENT TO LEASE AGREEMENT (“this Third Amendment”) is dated as of July 15, 2021 (“Third Amendment Effective Date”), by and between A |
|
| April 4, 2024 |
Exhibit 10.25 CUI LICENSE MODIFICATION 1 THIS modification to the Non-Exclusive License Agreement Control Number: “W8IXWH-”(“Modification 1”), effective upon the last signature date below, is made by and between: Walter Reed Armv Institute of Research (WRAIR) (hereinafter “LICENSOR”) a subordinate Laboratory of United States Army Medical Research and Materiel Command (“USAMRDC”), located at 503 Ro |
|
| April 4, 2024 |
Exhibit 10.32 FOURTH AMENDMENT TO LEASE AGREEMENT PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THIS FOURTH AMENDMENT TO LEASE AGREEMENT (“this Fourth Amendment”) is dated as of September 27 , 2022 (”Fourth Amendment Effective Date”), by and |
|
| April 4, 2024 |
Exhibit 10.23 FIRST AMENDMENT TO EXCLUSIVE LICENCE Between Adaptive Phage Therapeutics, Inc. And UNITED STATES OF AMERICA As Represented By THE SECRETARY OF THE NAVY PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. The parties agree to amend th |
|
| April 4, 2024 |
Exhibit 10.28 LEASE AGREEMENT PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THIS LEASE AGREEMENT (“this Lease”) is made as of this 9th day of August, 2019 between ARE-708 QUINCE ORCHARD, LLC, a Delaware limited liability company (“Landlord”) |
|
| April 4, 2024 |
Exhibit 10.22 EXCLUSIVE LICENSE Between Adaptive Phage Therapeutics, Inc. And UNITED STATES OF AMERICA As Represented By THE SECRETARY OF THE NAVY PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INDEX Page Preamble 1 Article 1 Definitions 1 Ar |
|
| April 4, 2024 |
Exhibit 107 Form S-8 (Form Type) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount registered(1)(2) Proposed maximum offering price per share Proposed maximum aggregate offering price Fee Rate Amount of registration fee Equity Common stock to be issued under the Chardan Healthcare Acquisition |
|
| April 4, 2024 |
Exhibit 97.1 BiomX Inc. (the “Company”) CLAWBACK POLICY Effective as of November 13, 2023 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board ha |
|
| April 4, 2024 |
Exhibit 10.29 FIRST AMENDMENT TO LEASE AGREEMENT PLEASE NOTE: CERTAIN INFORMATION INDICATED WITH [***] IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THIS FIRST AMENDMENT TO LEASE AGREEMENT (“this First Amendment”) is dated as of October 28, 2020 (“Effective Date”), by and between ARE-708 QUINCE |
|
| April 4, 2024 |
Exhibit 10.34 SIXTH AMENDMENT TO LEASE AGREEMENT THIS SIXTH AMENDMENT TO LEASE AGREEMENT (“Sixth Amendment”) is dated as of March 5, 2024 (“Amendment Date”), by and between ARE-708 QUINCE ORCHARD, LLC, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California 91101 (“Landlord”), and ADAPTIVE PHAGE THERAPEUTICS, INC., a Delaware corporation, having an a |
|
| April 4, 2024 |
Resolutions of Board of Directors Ratifying Stock Issuance Exhibit 99.1 RATIFICATION OF DEFECTIVE CORPORATE ACTION PURSUANT TO DGCL § 204 WHEREAS, at a meeting of the Board held on March 5, 2024, the Company approved the terms of a merger agreement (the “Merger Agreement”) to be entered into by and among the Company, BTX Merger Sub I, Inc. a Delaware corporation, BTX Merger Sub II, LLC a Delaware limited liability company, and Adaptive Phage Therapeutics, |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 3, 2024 |
Exhibit 99.1 BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline Closed concurrent $50 million financing to support BX004 and BX211 programs through key data readouts expected in 2025 Patient recruitment on track in BX211 Phase 2 trial |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: N/A Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 26, 2024 |
PHGE / BiomX Inc. / Cystic Fibrosis Foundation - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* BiomX Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 09090D103 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| March 25, 2024 |
PHGE / BiomX Inc. / AMR Action Fund, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) AMR Action Fund, L.P. c/o AMR |
|
| March 25, 2024 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| March 22, 2024 |
EX-99.1 2 e619413ex99-1.htm Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of BiomX, Inc. and further agree that this Join |
|
| March 22, 2024 |
PHGE / BiomX Inc. / Flynn James E Activist Investment SC 13D 1 e619413sc13d-biomx.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.l 3d-l (a) AND AMENDMENTS THERETO FILED PURSUANT TO§ 240.13D-2(a) (Amendment No. )* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) David Cl |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Comm |
|
| March 19, 2024 |
EX-99.1 2 ss3164415ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 4 to Schedule 13D, dated March 15, 2024, with respect to the common stock of BiomX Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersi |
|
| March 19, 2024 |
SC 13D/A 1 ss3164415sc13da.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* BiomX Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Carl L. Gord |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 18, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* BiomX Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Carl L. Gordon Erez Chimovits 5 Hahoshlim Street Building B |
|
| March 8, 2024 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| March 6, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among BiomX Inc., a Delaware corporation; BTX Merger Sub I, Inc., a Delaware corporation; BTX Merger Sub II, LLC, a Delaware limited liability company; and Adaptive Phage Therapeutics, Inc., a Delaware corporation Dated as of March 6, 2024 Table of Contents Page Article I DESCRIPTION OF TRANSACTION 3 Section 1.1 The Merger 3 Section 1.2 Effects of th |
|
| March 6, 2024 |
Exhibit 99.3 Revolutionizing the Treatment of Serious Infections Through Phage Therapy Corporate Presentation / March 2024 Exhibit 99.3 About this Presentation The information contained in this presentation has been prepared by BiomX Inc. and its subsidiaries (collectively, the “Company” or “BiomX”) and contains information pertaining to the business and operations of the Company. The information |
|
| March 6, 2024 |
Exhibit 3.1 BIOMX INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of BiomX Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Board of Directors o |
|
| March 6, 2024 |
Exhibit 4.3 FORM OF PLACEMENT AGENT WARRANT NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT |
|
| March 6, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of March 6, 2024, by and among BiomX Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement |
|
| March 6, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 6, 2024, by and among BiomX Inc., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser is executing and deli |
|
| March 6, 2024 |
FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT BIOMX INC. SUPPORT AGREEMENT Exhibit 99.1 FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT BIOMX INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of March [ ], 2024, is made by and among BiomX Inc., a Delaware corporation (“Parent”), Adaptive Phage Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Parent. WH |
|
| March 6, 2024 |
Exhibit 4.2 FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN |
|
| March 6, 2024 |
Exhibit 99.2 FORM OF LOCK-UP AGREEMENT March [], 2024 BiomX Inc. 22 Einstein St., Floor 4 Ness Ziona, Israel Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that BiomX Inc. a Delaware corporation (including any successor thereto, “Parent”), has entered into an Agreement and Plan of Merger, dated as of March 6, 2024 (as the same may b |
|
| March 6, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 13, 2024 |
PHGE / BiomX Inc. / MMCAP International Inc. SPC - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 2, 2024 |
PHGE / BiomX Inc. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 BiomX Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 09090D103 (CUSIP Number) December 31, 2023 (Date of Event Which |
|
| January 30, 2024 |
PHGE / BiomX Inc. / Cystic Fibrosis Foundation - SC 13G/A Passive Investment SC 13G/A 1 d744616dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BiomX Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 09090D103 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| December 29, 2023 |
BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 December 29, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: BiomX Inc. (CIK 0001739174) Registration Statement on Form S-3 (File No. 333-275935) (the “Registration Statement”) Request for Acceleration of Eff |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 12, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOMX INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 par value (Title of Class of Securities) 09090D103 (CUSIP Number of Class of Securities’ Underlyi |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 7, 2023 |
CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 Exhibit 99.1 Item 8. Financial Statements and Supplementary Data CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022 CONTENTS Page REPORT OF INDEPENDENT REGISTERED ACCOUNTING FIRM (PCAOB name: Kesselman & Kesselman C.P.A.s , PCAOB ID:1309) F-2 CONSOLIDATED FINANCIAL STATEMENTS: Consolidated Balance Sheets F-3 - F-4 Consolidated Statements of Operations F-5 Consolidated Statements of Changes in Sto |
|
| December 7, 2023 |
As filed with the Securities and Exchange Commission on December 7, 2023 As filed with the Securities and Exchange Commission on December 7, 2023 Registration No. |
|
| December 7, 2023 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT December 7, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: BiomX Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement |
|
| December 7, 2023 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) BIOMX INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 29, 2023 |
Exhibit 99.1 Revolutionizing the treatment of Cystic Fibrosis through our unique BOLT Phage therapy platform Investor Presentation / November 2023 2 Safe Harbor Statement This presentation contains certain “forward - looking statements” within the meaning of the “safe harbor” provisions of the U . S . Private Securities Litigation Reform Act of 1995 . Forward - looking statements can be identified |
|
| November 28, 2023 |
Offer to Exchange Certain Outstanding Stok Options for New Stock Options. Exhibit (a)(1)(A) BIOMX INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS This Offer and withdrawal rights will expire at 11:59 p.m., Israel Time, on December 11, 2023, unless we extend them. By this offer (the “Offer”), BiomX Inc. (“BiomX,” the “Company,” “we,” “our” or “us”) is giving eligible employees or consultants of BiomX the opportunity to exchange some or all |
|
| November 28, 2023 |
BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 November 28, 2023 Via EDGAR Christina Chalk Laura McKenzie Eddie Kim Securities and Exchange Commission Division of Corporation Finance Office of Mergers & Acquisition Washington, DC 20549 Re: BiomX Inc. (the “Company,” “we,” “our” and similar terminology) Schedule TO-I Filed November 9, 2023 File No. 005-90744 Dear Sir and Madam: The |
|
| November 28, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOMX INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 par value (Title of Class of Securities) 09090D103 (CUSIP Number of Class of Securities’ Underlyi |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact |
|
| November 14, 2023 |
Form of Indemnification Agreement Exhibit 10.2 BIOMX INC. Indemnification Agreement This Indemnification Agreement (this “Agreement”) is made as of, by and between BiomX Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases in the cost of such insu |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 14, 2023 |
Exhibit 99.1 BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month BX004 received FDA Fast Track designation in August Part 1 data recently presented at the North American Cystic Fibrosis Conference (NACFC) CAMBRIDGE, MA and NESS ZIONA, Israel – Nov 14 |
|
| November 9, 2023 |
Exhibit (a)(1)(D) Form of Election Name: Date and Time: Please identify your eligible option grants and new options grants below. |
|
| November 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOMX INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.0001 par value (Title of Class of Securities) 09090D103 (CUSIP Number of Class of Securities’ Underlying Common Stock) Jon |
|
| November 9, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form TO-I (Form Type) BiomX Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Table 1: Transaction Valuation Transaction Valuation (1) Fee Rate Amount of Filing Fee Fees to Be Paid $ 136,037 0.0001476 $ 20.08 Fees Previously Paid $ 0.00 — $ 0.00 Total Transaction Valuation $ 136,037 — — Total Fees Due for Filing — — $ 20.08 Total Fees P |
|
| November 9, 2023 |
Exhibit (a)(1)(A) BIOMX INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS This Offer and withdrawal rights will expire at 11:59 p.m., Israel Time, on December 11, 2023, unless we extend them. By this offer (the “Offer”), BiomX Inc. (“BiomX,” the “Company,” “we,” “our” or “us”) is giving eligible employees or consultants of BiomX the opportunity to exchange some or all |
|
| November 9, 2023 |
Election Terms and Conditions. Exhibit (a)(1)(C) BIOMX INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS ELECTION TERMS AND CONDITIONS 1. I agree that my decision to accept or reject the offer to exchange (the “Offer”) with respect to some or all of my eligible option grants is entirely voluntary and is subject to the terms and conditions of the Offer. 2. I understand that I may change my election a |
|
| November 9, 2023 |
Exhibit (a)(1)(B) Email to All Eligible Employees From: Marina Wolfson, Chief Financial Officer, BiomX Inc. |
|
| November 9, 2023 |
Exhibit (a)(1)(F) Stock Option Exchange 2 • Stock options are part of our compensation to our employees . |
|
| November 9, 2023 |
Exhibit (a)(1)(E) Form of Confirmation Email BiomX Inc. (“BiomX”) has received your election via email at [email protected] by which you elected to accept or reject BiomX’s offer to exchange certain outstanding stock options for new stock options (the “Offer”) with respect to some or all of your outstanding eligible option grants, subject to the terms and conditions of the Offer. Your election has |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number |
|
| September 29, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of ordinary shares of BiomX Inc. Each of them is responsible for the timely filing of such Schedule 13G |
|
| September 29, 2023 |
PHGE / BiomX Inc / Centaurus Investments Ltd - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) Rodney Hodges Director c/o Gen |
|
| August 29, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 9, 2023 |
Exhibit 99.1 BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grants BX004 Fast Track designation Initial Data from Part 2 Now Expected in November 2023 Company Will Host a Conference Call and Webcast Today at 8:00 am ET CAMBRIDGE, Ma |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 23, 2023 |
PHGE / BiomX Inc / Burbank John Howard III - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BiomX Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) May 4, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| June 20, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 12, 2023 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the Warrants, each exercisable for one-half of a share of common stock, at an exercise price of $11. |
|
| June 9, 2023 |
BIOMX INC. 31,775,477 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333- 272371 PROSPECTUS BIOMX INC. 31,775,477 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus or their permitted transferees (the “Selling Stockholders”) of up to 31,775,477 shares of our common stock, par value $0.0001 per share (“Common Stock”), 14,610,714 of which are issuable upon |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 (June 2, 2023) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2023 |
BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 BIOMX INC. 22 Einstein St., Floor 4 Ness Ziona, Israel 7414003 June 6, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: BiomX Inc. (CIK 0001739174) Registration Statement on Form S-3 (File No. 333-272371) (the “Registration Statement”) Request for Acceleration of Effectiv |
|
| June 2, 2023 |
As filed with the Securities and Exchange Commission on June 2, 2023 As filed with the Securities and Exchange Commission on June 2, 2023 Registration No. |
|
| June 2, 2023 |
Exhibit 107 Filing Fee Table Form S-3 (Form Type) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount registered (1)(2) Proposed maximum offering price per share(3) Proposed maximum aggregate offering price Fee Rate Amount of registration fee Fees to be Paid Equity |
|
| May 15, 2023 |
Exhibit 99.1 BiomX Reports First Quarter 2023 Financial Results and Provides Business Update Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”); Results from Part 2 Expected in Third Quarter of 2023 Second and Final Closing of PIPE Investment Completed, Raising Total Gross Proceeds of $7.5 million; Cash Runway int |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Nam |
|
| May 15, 2023 |
Form of Indemnification Agreement Exhibit 10.1 BIOMX INC. Indemnification Agreement This Indemnification Agreement (this “Agreement”) is made as of, by and between BiomX Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases in the cost of such insu |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 (May 11, 2023) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2)* Under the Securities Exchange Act of 1934 BiomX Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Carl L. Gordon Erez Chimovits 5 Hahoshlim Street Building B |
|
| May 5, 2023 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 (May 4, 2023) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 (April 24, 2023) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commiss |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0001-38762 BIOMX INC. (Exact name of regi |
|
| March 29, 2023 |
Exhibit 107 Form S-8 (Form Type) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount registered (1)(2) Proposed maximum offering price per share Proposed maximum aggregate offering price Fee Rate Amount of registration fee Equity Common stock to be issued under the Chardan Healthcare Acquisitio |
|
| March 29, 2023 |
As filed with the Securities and Exchange Commission on March 29, 2023 S-8 1 ea176021-s8biomxinc.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on March 29, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOMX INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2836 82-3364020 (State or other jurisdicti |
|
| March 29, 2023 |
Exhibit 99.1 BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”) Patient Enrollment Continues in Part 2 of Phase 1b/2a Trial with Results Expected in Third Quarter of 2023 Cash Runway Through at Least Mid-2024 Company Wil |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 17, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 BiomX Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 09090D103 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Carl L. Gordon Erez Chimovits Nissim Darvish 5 Hahoshlim St |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 8, 2023 |
PHGE / BiomX Inc / Cystic Fibrosis Foundation - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 BiomX Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 09090D103 (CUSIP Number) February 27, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 27, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 22, 2023 |
Form of Securities Purchase Agreement dated February 22, 2023 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 22, 2023, by and between BiomX Inc., a Delaware corporation (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 22, 2023 |
Exhibit 99.1 Revolutionizing the treatment of Cystic Fibrosis through our unique BOLT Phage therapy platform Investor Presentation / Jan 2023 2 Safe Harbor Statement This presentation contains certain “forward - looking statements” within the meaning of the “safe harbor” provisions of the U . S . Private Securities Litigation Reform Act of 1995 . Forward - looking statements can be identified by w |
|
| February 22, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 22, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February [●], 2023, by and among BiomX Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). This Agreement is made p |
|
| February 14, 2023 |
PHGE / Biomx Inc / MMCAP International Inc. SPC - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2023 |
PHGE / Biomx Inc / Ugwumba Chidozie - SCHEDULE 13G/A (AMENDMENT NO. 2) Passive Investment SC 13G/A 1 bio-sc13ga12312022.htm SCHEDULE 13G/A (AMENDMENT NO. 2) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 2)* BiomX Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securit |
|
| January 26, 2023 |
EX-99.1 2 ea172242ex99-1biomx.htm INVESTOR PRESENTATION DATED JANUARY 26, 2023 Exhibit 99.1 Revolutionizing the treatment of Cystic Fibrosis through our unique BOLT Phage therapy platform Investor Presentation / Jan 2023 2 Safe Harbor Statement This presentation contains certain “forward - looking statements” within the meaning of the “safe harbor” provisions of the U . S . Private Securities Liti |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2023 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 (January 5, 2023) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2022 |
PHGE / Biomx Inc / Ugwumba Chidozie - SCHEDULE 13 G/A (AMENDMENT NO. 1) Passive Investment SC 13G/A 1 bio-sc13gaamendment1.htm SCHEDULE 13 G/A (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (AMENDMENT NO. 1) BiomX Inc. (Name of Issuer) Common Stock, $0.0001 pa |
|
| November 9, 2022 |
Exhibit 99.1 BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023 Announced Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Precl |
|
| November 9, 2022 |
Exhibit 99.2 ? 2020 BiomX LTD. All rights reserved Company Introduction Safe Harbor Statement 2 This presentation contains certain ?forward - looking statements? within the meaning of the ?safe harbor? provisions of the U . S . Private Securities Litigation Reform Act of 1995 . Forward - looking statements can be identified by words such as : ?target,? ?believe,? ?expect,? ?will,? ?may,? ?anticipa |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact |
|
| November 9, 2022 |
Exhibit 3.1 BIOMX INC. COMPOSITE CERTIFICATE OF INCORPORATION INCORPORATING: Amended and Restated Certificate of Incorporation filed December 13, 2018 Certificate of Amendment of Certificate of Incorporation filed October 28, 2019 Certificate of Amendment of Certificate of Incorporation filed August 31, 2022 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMX INC. Pursuant to Section 245 of |
|
| November 9, 2022 |
Exhibit 3.2 BIOMX INC. COMPOSITE CERTIFICATE OF INCORPORATION INCORPORATING: Amended and Restated Certificate of Incorporation filed December 13, 2018 Certificate of Amendment of Certificate of Incorporation filed October 28, 2019 Certificate of Amendment of Certificate of Incorporation filed August 31, 2022 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMX INC. Pursuant to Section 245 of |
|
| August 29, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2022 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Name |
|
| August 10, 2022 |
Exhibit 99.1 BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update Enrollment Continues in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (?CF?); results from Part 1 expected by the end of Q3 2022 Entered into Second Collaboration with Boehringer Ingelheim to Discover Microbiome Markers for Inflammatory Bowel Disease Announced Publications i |
|
| August 5, 2022 |
PHGE / Biomx Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 Exit Filing)* BIOMX INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09090D103 (CUSIP Number) March 25, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| August 5, 2022 |
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited?s beneficial ownership of the reported securities is comprised of 1,478,286 shares of Common Stock held by Takeda Ventures, Inc., a wholly-owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned d |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2022 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 (June 26, 2022) BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commissio |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 14, 2022 |
Shareholder Director Nominations, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2022 BIOMX INC. |
|
| June 14, 2022 |
Exhibit 99.1 ? 2020 BiomX LTD. All rights reserved Company Introduction Safe Harbor Statement This presentation contains certain ?forward - looking statements? within the meaning of the ?safe harbor? provisions of the U . S . Private Securities Litigation Reform Act of 1995 . Forward - looking statements can be identified by words such as : ?target,? ?believe,? ?expect,? ?will,? ?may,? ?anticipate |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38762 BiomX Inc. (Exact Nam |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 BiomX Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38762 82-3364020 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 11, 2022 |
Exhibit 99.1 BiomX Reports First Quarter 2022 Financial Results and Provides Business Update Upcoming KOL Webinar Scheduled for May 12th to Discuss BX004 in Cystic Fibrosis IND Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis Cash Runway Through Multiple Data Readouts Company Will Host a Conference Call and Webcast Today at 8:00 am ET BRANFORD, Conn. and NESS ZI |
